Definium Therapeutics, Inc. - 8-K Filing
Definium Therapeutics reported $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, sufficient to fund operations into 2028. The company provided updates on its DT120 ODT clinical trials, including completed enrollment in Emerge (MDD) and Voyage (GAD), and plans to initiate the Haven (PTSD) Phase 3 study in 2027. Three Phase 3 topline data readouts for DT120 ODT are expected in the coming months. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MNMD